Etzer Darout
Stock Analyst at Barclays
(3.46)
# 965
Out of 5,008 analysts
120
Total ratings
47.31%
Success rate
5.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Equal-Weight | $112 → $97 | $94.39 | +2.77% | 8 | Sep 30, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $45 → $44 | $39.50 | +11.39% | 6 | Sep 24, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $8 → $10 | $2.26 | +342.48% | 5 | Sep 23, 2025 | |
| XNCR Xencor | Assumes: Underweight | $6 | $12.03 | -50.12% | 6 | Sep 17, 2025 | |
| MGNX MacroGenics | Assumes: Overweight | $3 | $1.72 | +74.42% | 10 | Sep 17, 2025 | |
| EXEL Exelixis | Initiates: Equal-Weight | $40 | $39.63 | +0.93% | 4 | Sep 17, 2025 | |
| CTMX CytomX Therapeutics | Assumes: Overweight | $3.5 | $3.33 | +5.11% | 11 | Sep 17, 2025 | |
| ARVN Arvinas | Assumes: Overweight | $16 | $9.30 | +72.04% | 5 | Sep 17, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Overweight | $15 | $7.99 | +87.73% | 6 | Sep 17, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underweight | $13 | $22.29 | -41.68% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $65.49 | +9.94% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $56.92 | +5.41% | 2 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $47 | $22.69 | +107.14% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $5.52 | +135.51% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $106.06 | +34.83% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $2.52 | +19.05% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $47.89 | +4.41% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $9.83 | +256.05% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.43 | +2,492.59% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.91 | +1,313.61% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $83.38 | +60.71% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $32.64 | +47.06% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $131.55 | -8.78% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.39 | +331.65% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $85.87 | -4.51% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.42 | +329.86% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $459.58 | -63.01% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $46.00 | +17.39% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $73.74 | -48.47% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.84 | +2,726.09% | 1 | Mar 28, 2018 |
Merus
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $94.39
Upside: +2.77%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $39.50
Upside: +11.39%
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.26
Upside: +342.48%
Xencor
Sep 17, 2025
Assumes: Underweight
Price Target: $6
Current: $12.03
Upside: -50.12%
MacroGenics
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.72
Upside: +74.42%
Exelixis
Sep 17, 2025
Initiates: Equal-Weight
Price Target: $40
Current: $39.63
Upside: +0.93%
CytomX Therapeutics
Sep 17, 2025
Assumes: Overweight
Price Target: $3.5
Current: $3.33
Upside: +5.11%
Arvinas
Sep 17, 2025
Assumes: Overweight
Price Target: $16
Current: $9.30
Upside: +72.04%
Terns Pharmaceuticals
Sep 17, 2025
Initiates: Overweight
Price Target: $15
Current: $7.99
Upside: +87.73%
Summit Therapeutics
Sep 17, 2025
Initiates: Underweight
Price Target: $13
Current: $22.29
Upside: -41.68%
Sep 17, 2025
Initiates: Overweight
Price Target: $72
Current: $65.49
Upside: +9.94%
Sep 17, 2025
Initiates: Overweight
Price Target: $60
Current: $56.92
Upside: +5.41%
Sep 17, 2025
Initiates: Overweight
Price Target: $47
Current: $22.69
Upside: +107.14%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.52
Upside: +135.51%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $106.06
Upside: +34.83%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.52
Upside: +19.05%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $47.89
Upside: +4.41%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $9.83
Upside: +256.05%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.43
Upside: +2,492.59%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.91
Upside: +1,313.61%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $83.38
Upside: +60.71%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $32.64
Upside: +47.06%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $131.55
Upside: -8.78%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.39
Upside: +331.65%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $85.87
Upside: -4.51%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.42
Upside: +329.86%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $459.58
Upside: -63.01%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $46.00
Upside: +17.39%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $73.74
Upside: -48.47%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.84
Upside: +2,726.09%